S-1/A: Mitesco Shifts to Data Centers, Faces Going Concern Doubt
Registration Statement Amendment
Mitesco, Inc. is undergoing a significant business model transformation, pivoting from unprofitable medical clinics to data center services and AI software development, while grappling with substantial debt and a going concern warning.
Summary
- Mitesco, Inc. (MITI) has transitioned from operating general practice medical clinics (The Good Clinic) to becoming a holding company focused on data center services and AI-based software development.
- The company closed its entire clinic operation in Q4 FY2022 due to lack of profitability, with financial results and obligations now accounted for as discontinued operations.
- New wholly-owned business units, Centcore, LLC (data center services) and Vero Technology Ventures, LLC (investment and acquisition in cloud computing/data centers, AI application development), were formed in June 2024.
- Centcore offers generic data center services, including cloud computing and application hosting, through a co-location agreement in Melbourne, Florida, with plans for rapid expansion and evaluation of smaller data centers.
- Vero Technology Ventures is developing an AI-based application called 'Robo Agent' for the sales process in residential real estate, expected for initial users in Q4 FY2025, and has secured a contract for a sports/pickleball arena listing application due late FY2026.
- A significant debt restructuring occurred in FY2024 and continued into FY2025, converting approximately $26.5 million of obligations (senior securities, notes, accounts payable) into 2,628,179 shares of restricted Common Stock and 562,998 shares of Series A Preferred Stock.
- As of September 30, 2025, the company had cash and cash equivalents of approximately $300 and current liabilities of approximately $17.6 million, leading to substantial doubt about its ability to continue as a going concern.
- Net loss available to common shareholders for the nine months ended September 30, 2025, was $116,984, a significant improvement from a net loss of $692,127 in the comparable period of 2024.
- Total operating expenses for the nine months ended September 30, 2025, increased to $1,668,862 from $721,095 in the comparable period of 2024, primarily due to new subsidiary operations and stock-based compensation.
- Interest expense for the nine months ended September 30, 2025, was $1,137,355, up from $159,206 in the prior period, mainly due to Series A preferred shares accretion and legal settlement interest.
- The company recorded a gain on revaluation of derivative liabilities of $3,513,655 for the nine months ended September 30, 2025, but also a loss on revaluation of Series A preferred shares of $646,653.
- A Senior Secured 10% Original Issue Discount Convertible Promissory Note (2025 Bridge Note) for up to $1 million (initial funding $250,000) was entered into on October 31, 2025, convertible at $0.15 per share.
- The registration statement covers the resale of up to 105,002,758 shares of common stock by selling stockholders, including shares from debt restructuring and potential conversion of the 2025 Bridge Note.
- The company will not receive any proceeds from the sale of shares by the selling stockholders under this prospectus.
Sentiment
Score: 2
Explanation: The company faces severe financial distress, evidenced by a 'going concern' warning, extremely low cash reserves, and significant liabilities. While a strategic pivot to data centers and AI is underway, it is in early stages with minimal revenue, and the potential for massive shareholder dilution from preferred stock redemptions is a major negative. The overall financial health and operational stability are highly precarious.
Positives
- Successful debt restructuring efforts have converted approximately $26.5 million of financial obligations into equity, reducing the immediate cash burden.
- Formation of new business units, Centcore (data center services) and Vero Technology Ventures (AI software, cloud computing investments), indicates a strategic pivot towards potentially high-growth sectors.
- Centcore's co-location agreement with a data center in Melbourne, Florida, provides immediate global expansion capability at minimal expense.
- Vero Technology Ventures has secured a contract for a new application related to sports and the pickleball arena, expected to be completed in late FY2026.
- The company reported a net income available to common shareholders of $116,984 for the nine months ended September 30, 2025, compared to a net loss of $692,127 in the prior comparable period, indicating improved profitability.
- A significant gain on revaluation of derivative liabilities of $3,513,655 was recorded for the nine months ended September 30, 2025.
- Waiver of all interest payments on Series F Preferred shares effective May 15, 2024, resulted in a reduction of accrued interest by over $200,000 per month.
Negatives
- There is substantial doubt about the company's ability to continue as a going concern due to limited operating history, recurring losses, and insufficient financial resources.
- As of September 30, 2025, the company had only approximately $300 in cash and cash equivalents and current liabilities of approximately $17.6 million.
- The company has a history of losses and nominal revenues from its current operations, with no assurance of future profitability.
- The issuance of up to 97,779,013 shares of common stock upon mandatory redemption of Series A Preferred Stock could cause approximately 90% dilution to existing shareholders.
- The market price of common stock has been volatile, dropping from $0.60 on November 26, 2024, to $0.14 on December 4, 2025.
- The company has identified material weaknesses in its internal controls, including lack of segregation of duties and insufficient resources for financial reporting.
- Outstanding legal settlements from the former clinic business amount to approximately $3.3 million, bearing interest at various rates.
- The company has no full-time employees, relying on directors and consultants, which may pose risks to operational stability and growth.
- The 2025 Bridge Note includes a 10% original issue discount and is secured by all company assets and subsidiary securities, indicating high-risk financing.
- The company will not receive any proceeds from the resale of shares by the selling stockholders in this offering.
Risks
- The company is in the initial stages of its present business plan and has a limited historical performance, with no assurance of profitability.
- Disruption or breach of security measures in data centers, cloud platforms, or IT systems could lead to reputational harm, legal exposure, and financial impact.
- Success is dependent on customer subscription and renewal of services, which is not guaranteed.
- Inability to attract and retain sufficient qualified personnel could harm the business.
- Involvement in legal proceedings, particularly from historical obligations, could result in significant monetary damages or injunctive relief.
- Failure to anticipate and adequately respond to rapid technological changes in the industry could materially and adversely affect the business.
- Operating in an intensely competitive industry with competitors having greater resources poses a significant challenge.
- Substantial doubt exists about the company's ability to continue as a going concern.
- Inability to generate significant revenue may necessitate raising additional capital, which may not be available on acceptable terms or at all.
- Future debt may contain restrictive covenants and impair operating flexibility.
- Identified material weaknesses in internal controls may not be effectively remediated, or additional weaknesses may occur.
- Issuance of additional common stock or convertible securities may dilute existing stockholders' ownership.
- Operating results and liquidity could be negatively affected by market fluctuations and economic downturns.
- Settlements with leaseholders and vendors create obligations that may hinder future financing.
- Evolving privacy laws, AI regulations, and cross-border data transfer restrictions may limit service adoption and adversely affect the business.
- Industry-specific regulations and standards are evolving, and unfavorable changes could harm the business.
- Acquisitions may subject the company to liabilities and integration difficulties.
- Dependence on senior management and key employees, with no full-time staff, poses a risk if these individuals are lost or cannot be replaced.
- Executive officers, directors, and certain key stockholders control a significant number of voting securities, potentially influencing stockholder voting outcomes.
- Shares eligible for future sale may have adverse effects on the share price.
- The common stock is considered a penny stock, subject to SEC rules that may reduce liquidity.
- No cash dividends are anticipated in the foreseeable future, making capital appreciation the sole source of gain.
- Thinly traded common stock may prevent investors from selling at or near asking prices.
- Redemption of Series A Preferred Stock into common stock may lead to severe dilution.
- Resales of common stock by selling stockholders may cause the market price to fall.
- Investors buying at different times may pay different prices and experience different dilution levels.
- Cybersecurity threats, unauthorized access, or breaches of information systems could lead to adverse consequences, including regulatory actions, litigation, financial loss, and reputational harm.
- Challenges in detection and response to cybersecurity breaches exist despite investments in measures.
Future Outlook
The company is a holding company seeking to provide products, services, and technology, with a focus on data center services and AI-based software development. The 'Robo Agent' AI application for residential real estate sales is expected to be available for initial users in Q4 FY2025, with later versions targeting other B2C markets. Another application for sports and pickleball arena listings is expected to be completed in late FY2026. The company expects to expand computing resources rapidly and cost-effectively through co-location agreements and by developing smaller data centers. Future growth is dependent on successful implementation of this new strategy and securing additional capital.
Management Comments
- Management continues to resolve its historical obligations through negotiation and use of its securities, though not all holders of its historical obligations appreciate the opportunity to own equity in the Company.
- We believe that the material weaknesses as reported will eventually be fully remediated, upon being properly capitalized to hire the proper personnel for segregation of duties and SEC and GAAP accounting knowledge.
- We believe our technology and services approach will be able to compete with other technology and services providers.
- We believe the principal competitive factors in our market include, but are not limited to: Focus on the cloud, Technology and services expertise, Customer experience, Speed of innovation, Strength of relationships with technology partners, Automation and scalability, Standardized operational processes, Geographic reach, Brand recognition and reputation, Price.
- We aspire to compare favorably on the basis of the factors listed above.
Industry Context
Mitesco's pivot to data center services and AI software development aligns with broader industry trends of increasing demand for cloud infrastructure, managed services, and artificial intelligence solutions. The company aims to compete in a highly competitive market by focusing on cloud technology, expertise, customer experience, and rapid innovation. Its strategy of developing smaller format data centers and AI applications for specific B2C markets like residential real estate and sports/pickleball arenas indicates an attempt to carve out niche markets within these growing sectors. However, it faces established competitors with significantly greater resources and market share.
Comparison to Industry Standards
- The company is in the early stage of developing its data center business and faces competition from established players with greater name recognition, longer operating histories, and significantly greater resources.
- Competitors include traditional global IT systems integrators like Accenture, Atos, Capgemini, Cognizant, Deloitte, DXC Technology, and IBM, which offer labor-intensive models for large enterprises.
- Cloud service providers and digital systems integrators offer consultation and implementation services for digital workflows or cloud services for single cloud vendors, often with narrow scope.
- Regional and national managed services providers use local go-to-market approaches and provide cloud services such as AWS, Microsoft Azure, and Google Cloud Platform (GCP).
- Colocation providers like Equinix, CyrusOne, and QTS offer secure hardware environments and network connectivity but provide limited service differentiation compared to Mitesco's managed services approach.
- Mitesco's strategy of developing smaller format (5,000 to 10,000 square foot) data centers inside existing facilities is a potential differentiator, aiming for minimal capital expenditure by leveraging existing power, backup generators, HVAC, water, and security infrastructure, which could offer a cost advantage over large-scale data center builds.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director | John Mitchell | 2025-05-27 | Resignation | |
| Director | Jim Clifton | 2025-05-26 | Appointment to the Board of Directors, previously served on Advisory Board. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Committee Composition | Jim Clifton appointed to the Compensation Committee. | 2025-05-26 | Adds a new member to the compensation committee, potentially bringing new perspectives to executive and director compensation policies. |
| Director Independence | Dr. Jordan Balencic is the only independent board member according to NASDAQ independence standards. | Indicates a board with limited independent oversight, as Mr. Leath is not independent due to executive roles. This could raise concerns about potential conflicts of interest or management accountability. | |
| Stock Option Plan Termination | The Mitesco Omnibus Securities and Incentive Plan and all previously issued options were canceled, revoked, and terminated. | 2024-01-07 | Eliminates existing stock option incentives and the framework for future equity compensation under that plan, potentially impacting employee and director motivation or future compensation strategies. |
Legal Proceedings
- The company has approximately $3.3 million in legal settlements and consent judgments arising from the closure of its clinic business, bearing interest at various local statutory rates.
- A Summary Judgment was granted on December 4, 2023, for the Eagan Clinic (Vikings) in the amount of $488,491, with final judgment entered on December 15, 2023.
- A stipulation for Judgment was filed on December 21, 2023, for the St. Paul Clinic (The Grove) in the amount of $415,266, with final judgment entered on January 19, 2024.
- A Confession of Judgment was executed on April 2, 2024, for the St. Louis Park Clinic (Excelsior & Grand) in the amount of $425,350, with the recorded judgment received on April 10, 2024.
- The company settled amounts owed to the leaseholder for the Radiant Clinic (Denver, CO) for approximately $530,000 as of April 10, 2024.
- A Final Judgment was granted on November 14, 2023, for the Quincy Clinic (Denver, CO) in the amount of $348,764, and an additional judgment of $500,000 was provided on August 8, 2025, to settle a modification action.
- The company is continuing efforts to negotiate a settlement of any remaining obligations to Gardner Builders Holdings, LLC, currently represented as a $2.2 million obligation in financial statements, expected to be resolved through an equity issuance.
Related Party Transactions
- The sale of remaining assets of The Good Clinic, LLC on December 8, 2023, to Leading Primary Care LLC, a company organized by Michael C. Howe (former CEO of The Good Clinic, LLC), involved cancelling approximately $2.5 million in notes payable and accrued interest owed to Mr. Howe. The company recognized a contribution to capital of approximately $2.5 million due to Mr. Howe being a related party.
- On December 8, 2023, Mr. Howe exchanged Series D Preferred Stock and accrued dividends, and accrued salary, for Series F Preferred Stock. Other than a $25,000 conversion incentive, no gain or loss was recorded.
- During Q4 of 2024, Mr. Howe exchanged all remaining obligations into restricted common stock using a $4 per share valuation.
- The acquisition of AgingTopic, LLC on December 6, 2024, involved a source code license agreement with an entity controlled by Ms. Amy Lance, the wife of Mack Leath (CEO, CFO, Chairman of the Board). The agreement included a $5,000 cash payment and royalty payments up to $150,000.
- On April 24, 2025, the company entered into Obligation Exchange Agreements with Finnegan and Lindstrom (former officers/related parties), settling notes, accrued interest, and other obligations for 75,000 shares of restricted common stock each, resulting in a gain on settlement of liabilities of $553,403.
- During the nine months ended September 30, 2025, the company issued 2,400 shares of Series X Preferred Stock to a newly elected director (Jim Clifton) for compensation in lieu of services in the amount of $60,000.
- During the nine months ended September 30, 2025, the company issued 20,000 shares of Series X Preferred Stock to an institutional investor and consultant for compensation in lieu of services in the amount of $500,000.
- On October 31, 2025, the company entered into a Senior Secured 10% Original Issue Discount Convertible Promissory Note (2025 Bridge Note) with C/M Capital Master Fund, L.P., one of its historical institutional investors, for potential funding of $1 million.
- Mack Leath (CEO, CFO, Chairman) and Jordan Balencic (Director) hold Series X Preferred Stock and common stock, giving them significant voting control (Leath 4.24%, Balencic 3.87% of total votes). Anglo Irish Management LLC, managed by Daniel Hollis, holds 41.57% of total votes, primarily from Series X Preferred Stock.
Stakeholder Impact
- **Shareholders:** Existing common shareholders face significant dilution risk (up to 90%) from the mandatory redemption of Series A Preferred Stock into common stock. The stock is thinly traded and volatile, and no cash dividends are expected. The 'going concern' warning indicates high investment risk.
- **Preferred Stockholders (Series A):** These institutional investors are receiving common stock in redemption of their preferred shares, potentially at a discount to market price, but also contributing to dilution.
- **Creditors/Vendors:** Many historical obligations have been converted into equity (common or Series A preferred stock) as part of the debt restructuring, reducing immediate cash payouts but potentially shifting risk to equity ownership. Some legal settlements remain as cash payment obligations.
- **Management/Directors:** Compensation includes restricted common stock and Series X Preferred Stock, aligning their interests with shareholders, but also contributing to stock-based compensation expense and potential dilution. They hold significant voting control.
- **Employees:** The company has no full-time employees, relying on consultants and directors, which impacts job security and traditional employee benefits. The closure of 'The Good Clinic' resulted in staff release.
Next Steps
- Continue development of the 'Robo Agent' AI application, with initial users expected in Q4 FY2025.
- Execute the contract for the sports and pickleball arena listing application, with completion expected in late FY2026.
- Evaluate and develop a network of smaller format data centers inside existing facilities.
- Resolve remaining historical obligations, including a $2.2 million obligation to Gardner Builders Holdings, LLC, likely through equity issuance.
- Remediate identified material weaknesses in internal controls by expanding staff and engaging consultants with appropriate GAAP and SEC accounting experience.
- Seek additional capital to fund operations and sustain the business as a going concern.
Key Dates
| Date | Description |
|---|---|
| 2012-01-18 | Mitesco, Inc. formed in Delaware. |
| 2015-12-09 | Restructured operations and acquired Newco4pharmacy, LLC, shutting down former business line. |
| 2020-04-24 | Company changed its name to Mitesco, Inc. |
| 2020-04-25 | Entered unsecured Promissory Note with Bank of America for a PPP Loan of $460,400. |
| 2020-05-04 | Received full proceeds of the PPP Loan. |
| 2020-11-01 | Entered agreement to open Nordhaus Clinic in Minneapolis, MN. |
| 2021-Q1 | Opened first 'The Good Clinic' in Minneapolis, Minnesota. |
| 2021-05-24 | Entered agreement to open St. Louis Park Clinic (Excelsior & Grand). |
| 2021-06-08 | Entered agreement to open Eden Prairie Clinic (TP Elevate). |
| 2021-06-24 | Entered agreement to open an administrative office in St. Louis Park, Minnesota. |
| 2021-08-31 | Entered agreement to open St. Paul Clinic (The Grove). |
| 2021-09-09 | Entered agreement to open Radiant Clinic in Denver, Colorado. |
| 2021-09-28 | Entered agreement to open Quincy Clinic in Denver, Colorado. |
| 2021-10-14 | Entered agreement to open Eagan Clinic (Vikings). |
| 2021-10-08 | Entered agreement to open Maple Grove Clinic (Arbor Lakes). |
| 2021-12-30 | Issued Howe Note 1 for $1,000,000 to Michael C. Howe Living Trust. |
| 2022-01-07 | Entered debt-for-equity exchange agreement with Gardner Builders Holdings, LLC. |
| 2022-03-18 | Entered Securities Purchase Agreement with AJB Capital Investments, LLC. |
| 2022-04-06 | Entered Securities Purchase Agreement with Anson Investments Master Fund LP and Anson East Master Fund LP. |
| 2022-04-18 | Entered Securities Purchase Agreement with GS Capital Investments, LLC. |
| 2022-05-10 | Entered Securities Purchase Agreement with Kishon Investments, LLC. |
| 2022-05-23 | Issued Finnegan Note 1 to Jessica Finnegan. |
| 2022-05-26 | Issued Finnegan Note 2 to Jessica Finnegan, M Diamond Note to Melissa Diamond, and Dobbertin Note to Alexander Dobbertin. |
| 2022-06-09 | Issued Howe Note 2 to Michael C. Howe Living Trust. |
| 2022-07-07 | Issued Schrier Note to Charles Schrier. |
| 2022-07-21 | Issued Howe Note 3 to Michael C. Howe Living Trust. |
| 2022-07-26 | Issued Nommsen Note to Eric S. Nommsen. |
| 2022-07-27 | Issued Caplan Note to James H. Caplan. |
| 2022-08-04 | Issued Finnegan Note 3 to Jessica, Kevin C., Brody, Isabella and Jack Finnegan. |
| 2022-08-18 | Issued Howe Note 4 to Michael C. Howe Living Trust. |
| 2022-09-02 | Issued Lightmas Note to Frank Lightmas, Lewis Note to Lisa Lewis, Goff Note to Sharon Goff, and Mitchell Note to John Mitchell. |
| 2022-09-09 | Issued Hagan Note to Cliff Hagan. |
| 2022-09-15 | Issued Leath Note to Mack Leath. |
| 2022-Q4 | Made strategic decision to close entire clinic operation and release staff due to lack of profitability. |
| 2022-10-22 | Entered settlement agreement with leaseholder for Maple Grove Clinic for $219,576. |
| 2022-11-29 | Issued seven identical promissory notes (November 29 Notes) to related parties. |
| 2023-03-23 | Filed Certificate of Designations, Preferences and Rights of Series F 12% PIK $0.01 par value Convertible Perpetual Preferred Stock. |
| 2023-04-11 | Converted various notes and preferred stock into Series F Preferred Stock for multiple investors. |
| 2023-07-12 | Received confirmation of payment plan arrangement from SBA for PPP Loan. |
| 2023-09-29 | Former COO and board member converted notes, accrued interest, salary, and board fees into 181,606 shares of common stock. |
| 2023-10-23 | Company changed its domicile from Delaware to Nevada to effect reduced costs. |
| 2023-11-06 | Received termination notice from landlord for Nordhaus Clinic lease. |
| 2023-11-14 | Final Judgment granted for Quincy Clinic in the amount of $348,764. |
| 2023-12-04 | Summary Judgment granted for Eagan Clinic in the amount of $488,491. |
| 2023-12-08 | Sold remaining assets of The Good Clinic, LLC to Leading Primary Care LLC, cancelling $2.5 million in notes payable and accrued interest owed to Michael C. Howe. |
| 2023-12-15 | Mack Leath and Dr. Jordan Balencic appointed to the Board of Directors. |
| 2023-12-21 | Stipulation for Judgment filed for St. Paul Clinic in the amount of $415,266. |
| 2024-01-07 | Board of Directors voted to cancel, revoke, and terminate all previously issued stock options and formally terminate the Mitesco Omnibus Securities and Incentive Plan. |
| 2024-01-19 | Final entry of judgment by the Court against the company for St. Paul Clinic. |
| 2024-02-27 | Dismissed RBSM LLP as independent registered public accountants. |
| 2024-04-02 | Executed Confession of Judgment for St. Louis Park Clinic in the amount of $425,350. |
| 2024-04-10 | Received fully executed and recorded judgment for St. Louis Park Clinic; settled amounts owed to leaseholder for Radiant Clinic for approximately $530,000. |
| 2024-05-15 | All dividends and obligations to pay dividends on Series F Preferred shares ceased. |
| 2024-06-12 | Informed that Accell Audit & Compliance, P.A. was ceasing PCAOB audit services. |
| 2024-06-30 | Company had over $30 million in senior securities, notes, and accounts payable related to discontinued operations. |
| 2024-Q4 | Issued 18,853 shares of restricted common stock for Series X preferred stock dividends; issued 225,000 shares of restricted common stock to Advisory Board members. |
| 2024-10-28 | Filed Certificate of Designation, Preferences and Rights of the Series A Preferred Stock. |
| 2024-12-04 | Last reported closing price of common stock was $0.14. |
| 2024-12-06 | Closed acquisition of AgingTopic, LLC, allocating $155,000 to domain name intangible assets. |
| 2024-12-31 | Converted $580,132 of 2024 Bridge Notes into Series A Preferred shares; all FY2024 bridge notes extinguished. |
| 2025-01-01 | Mandatory redemption of Series A Preferred Stock began at a rate of 1/36th monthly. |
| 2025-Q1 | Redemptions of Series A Preferred stock resulted in issuance of 1,366,394 shares of common stock and redemption of 20,098 Series A Preferred shares; 4,000 new Series A Preferred shares issued for $100,000. |
| 2025-04-14 | Issued 16,286 shares for February and March Series X dividends. |
| 2025-04-24 | Entered Obligation Exchange Agreements with Finnegan and Lindstrom, settling notes and obligations for 75,000 restricted common shares each. |
| 2025-05-26 | Jim Clifton appointed to the Board of Directors. |
| 2025-05-27 | John Mitchell resigned as a Director. |
| 2025-Q2 | Redemptions of Series A Preferred stock resulted in issuance of 402,450 shares of common stock and redemption of 4,252 Series A Preferred shares; no new Series A Preferred shares issued. |
| 2025-08-08 | Settled Quincy Clinic matter by providing an additional judgment of $500,000. |
| 2025-08 | Retained executive for Robo Agent development at $10,000/month; recruited three contract programmers. |
| 2025-09 | Received contract for new application related to sports/pickleball arena. |
| 2025-09-30 | Cash and cash equivalents approximately $300; current liabilities approximately $17.6 million. |
| 2025-Q3 | Redemptions of Series A Preferred stock resulted in issuance of 2,025,910 shares of common stock and redemption of 10,308 Series A Preferred shares; 1,000 new Series A Preferred shares issued for $25,000. |
| 2025-10-31 | Entered Senior Secured 10% Original Issue Discount Convertible Promissory Note (2025 Bridge Note) with C/M Capital Master Fund, L.P. for potential $1 million funding, initial $250,000. |
| 2025-11-13 | Cash of approximately $55,000. |
| 2025-12-05 | Date of filing of the S-1/A Registration Statement. |
Recommendation
strong sellThe company faces severe financial instability, explicitly stating 'substantial doubt about our ability to continue as a going concern.' Cash reserves are critically low ($300 as of September 30, 2025) against significant liabilities ($17.6 million current). While a strategic pivot to data centers and AI is underway, it is nascent and unproven, generating minimal revenue. The potential for up to 90% dilution from Series A Preferred Stock redemptions, coupled with a volatile and thinly traded stock, presents an extremely high risk for investors. The identified material weaknesses in internal controls further compound governance concerns. The overall risk profile is exceptionally high, making the stock a strong sell.
Keywords
Data Center Services, Cloud Computing, Artificial Intelligence, AI Software Development, SEC Filing, S-1/A, Debt Restructuring, Going Concern, Preferred Stock, Common Stock Dilution, Cybersecurity Risks, Financial Reporting, Corporate Governance, MITI, Technology Ventures, Managed Services
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.